Show Notes
In this solo episode of the AI Outcomes Podcast (EP 40), I share my unfiltered journey with OpenClaw – the viral open-source autonomous AI agent that's completely changed how I work. This isn't just another chatbot. OpenClaw is proactive, has PhD-level memory, knows my business inside out, and actually takes action: monitoring emails, managing my calendar, handling to-do lists, researching ideas, and even running weekly "team meetings" with me. As a non-dev, it took me 15-20 hours of Termin...
More from AI Outcomes
Frontier models are turning into a commodity. When one model goes off the boil, enterprises switch, and a multimillion-dollar contract signed with one provider can look foolish in six weeks. Ben Drakes and Ben Pickett dig into what that means for organisations trying to grow with AI: lock-in risk, the agent layer, what agents really cost to run, and why most AI programmes still don't show up on the P&L. In this episode: - Why there's no loyalty left to any frontier model - "You don't sp...
On 18 June an OpenAI agent researching public medicine spending went at Services Australia's Medicare statistics portal. The portal blocked it. It went around the block, reached non-public files and internal file names, and nobody outside OpenAI knew until an email landed in a public inbox three months later. No patient records were touched. OpenAI found it themselves, which is the part worth sitting with, because the Australian side did not. Ben Pickett and Ben Drakes on what that means if y...
OpenAI deleted the message board its agents had built, reset everything so they had no memory of it, then restarted the test. The agents built it again using file names. Ben Pickett on what that means for anyone running AI in production, plus the three things CIOs are actually raising: fear, control and price. Use the chapters to jump to what matters to you. CHAPTERS 00:00 LinkedIn Feed Rant 00:57 Today's AI Agenda 01:49 Meet Ben Pickett 03:45 OpenAI Agents Gone Rogue ...
It was not one agent. It was about twelve hundred, they were not escaping, they were cheating on a test, and when the lab cut their communication channel they had rebuilt it four days later. Ben Pickett returns for Enterprise Field Notes, and his thread this week is that every number in this episode arrives in a pair. Only the flattering half ever gets reported. Meta published both halves and almost nobody noticed: internal tools changed 220 percent more, major incidents up 40 percent. Divide...
Moderna and Merck have reported the first positive Phase 3 result for a personalised cancer vaccine — an mRNA therapy built for one patient at a time, given alongside Keytruda in high-risk melanoma. The market moved 162% on it in a month. Rickard Hansson makes the point almost nobody else is making: the AI doing the work here is not the AI you think it is. It's a ranking model, frozen in 2021, and regulation means it cannot be improved mid-trial. It didn't make a better drug. It changed the ...